Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

"Bioethics International reviewed therapies that have been offered through expanded access programs that were listed in ClinicalTrials.gov over the database’s entire history: 71% of requests have been for drugs; 11% were for biologics, and 10% were for medical devices. The review also found that 76% of the drugs that are provided through Expanded Access Programs end up receiving FDA approval."

The underlined phrase is important for statistical purposes. IPIX has not listed brilacidin for Covid-19 in the Clinical Trials registry. 13 other companies have listed their treatments (and they are currently available) and it is the companies that list their programs that are included in the statistics.

https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=&type=&rslt=&recrs=c&age_v=&gndr=&intr=&titles=&outc=&spons=&lead=&id=&cntry=&state=&city=&dist=&locn=&rsub=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=